Cancer represents an evolutionary process through which growing malignant populations
genetically diversify, leading to tumour progression, relapse and resistance to therapy. In …

The use of genomics is firmly established in clinical practice, resulting in innovations across
a wide range of disciplines such as genetic screening, rare disease diagnosis and …

Inactive state-selective KRAS (G12C) inhibitors,,,,,,–demonstrate a 30–40% response rate
and result in approximately 6-month median progression-free survival in patients with lung …

Myeloid malignancies, including acute myeloid leukaemia (AML), arise from the expansion
of haematopoietic stem and progenitor cells that acquire somatic mutations. Bulk molecular …

Despite high initial response rates, acute myeloid leukemia (AML) treated with the BCL-2–
selective inhibitor venetoclax (VEN) alone or in combinations commonly acquires …

The therapeutic armamentarium of acute myeloid leukemia (AML) has rapidly expanded in
the past few years, driven largely by translational research into its genomic landscape and …

Clonal diversity is a consequence of cancer cell evolution driven by Darwinian selection.
Precise characterization of clonal architecture is essential to understand the evolutionary …

Gilteritinib is a potent and selective FLT3 kinase inhibitor with single-agent clinical efficacy in
relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). In this context, however …

Advances in molecular biology, microfluidics and bioinformatics have empowered the study
of thousands or even millions of individual cells from malignant tumours at the single-cell …

With the combination of KRASG12C and EGFR inhibitors, KRAS is becoming a druggable
target in colorectal cancer. However, secondary resistance limits its efficacy. Using cell lines …